A Randomized, Double Masked, Three Dose Safety and Pharmacokinetic Study of RTH258 Following Intravitreal (IVT) Injection in Subjects With Neovascular Age-Related Macular Degeneration
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2016
At a glance
- Drugs Brolucizumab (Primary)
- Indications Age-related macular degeneration
- Focus Pharmacokinetics
- Sponsors Alcon
- 27 Sep 2016 Status changed from recruiting to completed.
- 19 May 2016 Planned End Date changed from 1 Nov 2016 to 1 Sep 2016.
- 19 May 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Sep 2016.